
Marc B I Lobbes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3402764/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Magnetic resonance imaging before breast cancer surgery: results of an observational multicenter international prospective analysisÂ(MIPA). European Radiology, 2022, 32, 1611-1623.	4.5	30
2	A feasibility study combining a magnetic seed and magnetic tracer in patients undergoing breast-conserving surgery combined with sentinel lymph node biopsy for nonpalpable breast lesions. European Journal of Surgical Oncology, 2022, 48, e74.	1.0	0
3	Test–Retest Data for the Assessment of Breast <scp>MRI</scp> Radiomic Feature Repeatability. Journal of Magnetic Resonance Imaging, 2022, 56, 592-604.	3.4	11
4	Contrast-enhanced mammography: what the radiologist needs to know. BJR Open, 2021, 3, 20210034.	0.6	11
5	Dedicated Axillary MRI-Based Radiomics Analysis for the Prediction of Axillary Lymph Node Metastasis in Breast Cancer. Cancers, 2021, 13, 757.	3.7	19
6	Abstract GS1-10: Radioactive lodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: Results of the prospective multicenter RISAS trial. Cancer Research, 2021, 81, GS1-10-GS1-10.	0.9	17
7	Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study. Journal of Hematology and Oncology, 2021, 14, 64.	17.0	61
8	Contrast-enhanced Mammography: State of the Art. Radiology, 2021, 299, 36-48.	7.3	133
9	Supplemental Breast MRI for Women with Extremely Dense Breasts: Results of the Second Screening Round of the DENSE Trial. Radiology, 2021, 299, 278-286.	7.3	66
10	MRI-Based Radiomics Analysis for the Pretreatment Prediction of Pathologic Complete Tumor Response to Neoadjuvant Systemic Therapy in Breast Cancer Patients: A Multicenter Study. Cancers, 2021, 13, 2447.	3.7	20
11	Reducing False-Positive Screening MRI Rate in Women with Extremely Dense Breasts Using Prediction Models Based on Data from the DENSE Trial. Radiology, 2021, 301, 283-292.	7.3	9
12	Contrast enhanced mammography (CEM) versus magnetic resonance imaging (MRI) for staging of breast cancer: The pro CEM perspective. European Journal of Radiology, 2021, 142, 109883.	2.6	19
13	Visualization of Both the Superficial and Deep Lymphatic System of the Upper Extremity Using Magnetic Resonance Lymphography. Lymphatic Research and Biology, 2021, , .	1.1	2
14	Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic. Preventive Medicine, 2021, 151, 106602.	3.4	48
15	Diagnostic Performance of Noninvasive Imaging for Assessment of Axillary Response After Neoadjuvant Systemic Therapy in Clinically Node-positive Breast Cancer. Annals of Surgery, 2021, 273, 694-700.	4.2	40
16	The diagnostic value of contrast-enhanced 2D mammography in everyday clinical use. Scientific Reports, 2021, 11, 22224.	3.3	1
17	Breast Implant Prevalence in the Dutch Female Population Assessed by Chest Radiographs. Aesthetic Surgery Journal, 2020, 40, 156-164.	1.6	20
18	Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. Annals of Surgery, 2020, 271, 574-580.	4.2	72

#	Article	IF	CITATIONS
19	Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk. JAMA Oncology, 2020, 6, 1381.	7.1	31
20	Al ‣nhanced Diagnosis of Challenging Lesions in Breast MRI : A Methodology and Application Primer. Journal of Magnetic Resonance Imaging, 2020, 54, 686-702.	3.4	26
21	The effect of breast MRI on disease-free and overall survival in breast cancer patients: a retrospective population-based study. Breast Cancer Research and Treatment, 2020, 184, 951-963.	2.5	4
22	MRI-based radiomics in breast cancer: feature robustness with respect to inter-observer segmentation variability. Scientific Reports, 2020, 10, 14163.	3.3	47
23	Solving the preoperative breast MRI conundrum: design and protocol of the MIPA study. European Radiology, 2020, 30, 5427-5436.	4.5	18
24	Diagnostic performance of standard breast MRI compared to dedicated axillary MRI for assessment of node-negative and node-positive breast cancer. European Radiology, 2020, 30, 4212-4222.	4.5	10
25	The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2020, 181, 581-588.	2.5	10
26	Response Assessment and Follow-Up by Imaging in Breast Tumors. Medical Radiology, 2020, , 451-474.	0.1	0
27	Risk of positive sentinel lymph node after neoadjuvant systemic therapy in clinically node negative breast cancer -implications for postmastectomy radiation therapy and immediate breast reconstruction. European Journal of Surgical Oncology, 2020, 46, e23.	1.0	0
28	Population-based study of the effect of preoperative breast MRI on the surgical management of ductal carcinoma <i>in situ</i> . British Journal of Surgery, 2019, 106, 1488-1494.	0.3	15
29	Post-mortem computed tomography in forensic investigations of lethal gunshot incidents: is there an added value?. International Journal of Legal Medicine, 2019, 133, 1889-1894.	2.2	6
30	Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction. Annals of Surgical Oncology, 2019, 26, 3902-3909.	1.5	2
31	Exploring breast cancer response prediction to neoadjuvant systemic therapy using MRI-based radiomics: A systematic review. European Journal of Radiology, 2019, 121, 108736.	2.6	63
32	Evaluation of pressure-controlled mammography compression paddles with respect to force-controlled compression paddles in clinical practice. European Radiology, 2019, 29, 2545-2552.	4.5	14
33	Does the subtype of breast cancer affect the diagnostic performance of axillary ultrasound for nodal staging in breast cancer patients?. European Journal of Surgical Oncology, 2019, 45, 573-577.	1.0	5
34	MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 1136-1147.	10.7	112
35	Reversal of the hanging protocol of Contrast Enhanced Mammography leads to similar diagnostic performance yet decreased reading times. European Journal of Radiology, 2019, 117, 62-68.	2.6	6

Interpretation of Contrast-Enhanced Mammography. , 2019, , 61-75.

#	Article	IF	CITATIONS
37	Evaluation of single-view contrast-enhanced mammography as novel reading strategy: a non-inferiority feasibility study. European Radiology, 2019, 29, 6211-6219.	4.5	5
38	Can high school students help to improve breast radiologists in detecting missed breast cancer lesions on full-field digital mammography?. Journal of Cancer, 2019, 10, 765-771.	2.5	4
39	Differences in degree of lesion enhancement on CEM between ILC and IDC. BJR Open, 2019, 1, 20180046.	0.6	11
40	Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. New England Journal of Medicine, 2019, 381, 2091-2102.	27.0	388
41	Rapid Access to Contrast-Enhanced spectral mammogRaphy in women recalled from breast cancer screening: the RACER trial study design. Trials, 2019, 20, 759.	1.6	11
42	Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy. Annals of Surgical Oncology, 2018, 25, 1350-1356.	1.5	80
43	Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast. JAMA Oncology, 2018, 4, 335.	7.1	229
44	Diagnostic performance of gadofosveset-enhanced axillary MRI for nodal (re)staging in breast cancer patients: results of a validation study. Clinical Radiology, 2018, 73, 168-175.	1.1	11
45	Contrast Enhanced Spectral Mammography: A Review. Seminars in Ultrasound, CT and MRI, 2018, 39, 70-79.	1.5	96
46	Multireader Study on the Diagnostic Accuracy of Ultrafast Breast Magnetic Resonance Imaging for Breast Cancer Screening. Investigative Radiology, 2018, 53, 579-586.	6.2	60
47	Comparison Between Breast MRI and Contrast-Enhanced Digital Mammography. , 2018, , 47-56.		0
48	Reasons for (non)participation in supplemental population-based MRI breast screening for women with extremely dense breasts. Clinical Radiology, 2018, 73, 759.e1-759.e9.	1.1	23
49	MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer. Breast Cancer Research, 2018, 20, 34.	5.0	47
50	Quantification of enhancement in contrast-enhanced spectral mammography using a custom-made quantifier tool (I-STRIP): A proof-of-concept study. European Journal of Radiology, 2018, 106, 114-121.	2.6	14
51	Breast lesion segmentation software for DCE-MRI: An open source GPGPU based optimization. , 2018, , .		1
52	Reply to Tagliafico AS, Bignotti B, Rossi F, etÂal Breast, 2017, 32, 267.	2.2	6
53	Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers. Breast Cancer Research and Treatment, 2017, 162, 353-364.	2.5	39
54	Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases. Breast Cancer Research and Treatment, 2017, 163, 159-166.	2.5	40

#	Article	IF	CITATIONS
55	Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment, 2017, 163, 83-91.	2.5	76
56	A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study. Clinical Breast Cancer, 2017, 17, 399-402.	2.4	91
57	Hybrid 18F–FDG PET/MRI might improve locoregional staging of breast cancer patients prior to neoadjuvant chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1796-1805.	6.4	28
58	Breast magnetic resonance imaging use in patients undergoing neoadjuvant chemotherapy is associated with less mastectomies in large ductal cancers but not in lobular cancers. European Journal of Cancer, 2017, 81, 74-80.	2.8	9
59	Contrast Media Administration in Coronary Computed Tomography Angiography – A Systematic Review. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2017, 189, 312-325.	1.3	18
60	Does the TNM classification of solitary internal mammary lymph node metastases in breast cancer still apply?. Breast Cancer Research and Treatment, 2017, 161, 483-489.	2.5	7
61	Clinical auditing as an instrument for quality improvement in breast cancer care in the Netherlands: The national NABON Breast Cancer Audit. Journal of Surgical Oncology, 2017, 115, 243-249.	1.7	62
62	Contrast-enhanced spectral mammography as work-up tool in patients recalled from breast cancer screening has low risks and might hold clinical benefits. European Journal of Radiology, 2017, 94, 31-37.	2.6	49
63	Dynamical Graph Theory Networks Methods for the Analysis of Sparse Functional Connectivity Networks and for Determining Pinning Observability in Brain Networks. Frontiers in Computational Neuroscience, 2017, 11, 87.	2.1	10
64	Assessing the Risk of Contrast-Induced Nephropathy Using a Finger Stick Analysis in Recalls from Breast Screening: The CINFIBS Explorative Study. Contrast Media and Molecular Imaging, 2017, 2017, 1-5.	0.8	7
65	Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08). BMC Cancer, 2017, 17, 459.	2.6	90
66	Contrast-enhanced spectral mammography in recalls from the Dutch breast cancer screening program: validation of results in a large multireader, multicase study. European Radiology, 2016, 26, 4371-4379.	4.5	98
67	Routine use of standard breast MRI compared to axillary ultrasound for differentiating between no, limited and advanced axillary nodal disease in newly diagnosed breast cancer patients. European Journal of Radiology, 2016, 85, 2288-2294.	2.6	62
68	Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study. Breast Cancer Research and Treatment, 2016, 156, 465-472.	2.5	49
69	Contrast-enhanced tomosynthesis: The best of both worlds or more of the same?. European Journal of Radiology, 2016, 85, 507-508.	2.6	8
70	Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer. European Journal of Cancer, 2016, 52, 67-76.	2.8	64
71	The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07). BMC Cancer, 2015, 15, 610.	2.6	65
72	Radiation Exposure of Digital Breast Tomosynthesis Using an Antiscatter Grid Compared With Full-Field Digital Mammography. Investigative Radiology, 2015, 50, 679-685.	6.2	19

#	Article	IF	CITATIONS
73	Diagnostic Performance of Dedicated Axillary T2- and Diffusion-weighted MR Imaging for Nodal Staging in Breast Cancer. Radiology, 2015, 275, 345-355.	7.3	53
74	Three-Dimensional Breast Radiotherapy and the Elective Radiation Dose at the Sentinel Lymph Node Site in Breast Cancer. Annals of Surgical Oncology, 2015, 22, 3824-3830.	1.5	12
75	MR Imaging as an Additional Screening Modality for the Detection of Breast Cancer in Women Aged 50–75 Years with Extremely Dense Breasts: The DENSE Trial Study Design. Radiology, 2015, 277, 527-537.	7.3	89
76	Evaluation of low-energy contrast-enhanced spectral mammography images by comparing them to full-field digital mammography using EUREF image quality criteria. European Radiology, 2015, 25, 2813-2820.	4.5	116
77	The Quality of Tumor Size Assessment by Contrast-Enhanced Spectral Mammography and the Benefit of Additional Breast MRI. Journal of Cancer, 2015, 6, 144-150.	2.5	99
78	The role of MRI in axillary lymph node imaging in breast cancer patients: a systematic review. Insights Into Imaging, 2015, 6, 203-215.	3.4	83
79	Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review. European Journal of Radiology, 2015, 84, 41-47.	2.6	43
80	Rapid Point-Of-Care Breath Test for Biomarkers of Breast Cancer and Abnormal Mammograms. PLoS ONE, 2014, 9, e90226.	2.5	48
81	Radiation Exposure of Contrast-Enhanced Spectral Mammography Compared With Full-Field Digital Mammography. Investigative Radiology, 2014, 49, 659-665.	6.2	83
82	The impact of the pathological lymph node status on adjuvant systemic treatment recommendations in clinically node negative breast cancer patients. Breast Cancer Research and Treatment, 2014, 143, 469-476.	2.5	21
83	Contrast-enhanced spectral mammography in patients referred from the breast cancer screening programme. European Radiology, 2014, 24, 1668-76.	4.5	136
84	A Model to Predict Pathologic Complete Response of Axillary Lymph Nodes to Neoadjuvant Chemo(Immuno)Therapy in Patients With Clinically Node-Positive Breast Cancer. Clinical Breast Cancer, 2014, 14, 315-322.	2.4	44
85	Contrast-Enhanced Dual-Energy Mammography: A Promising New Imaging Tool in Breast Cancer Detection. Women's Health, 2014, 10, 289-298.	1.5	17
86	The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Into Imaging, 2013, 4, 163-175.	3.4	173
87	Bilateral analysis of the cross-sectional area of the internal mammary arteries and veins in patients with and without breast cancer on breast magnetic resonance imaging. Insights Into Imaging, 2013, 4, 177-184.	3.4	8
88	Contrast enhanced mammography: Techniques, current results, and potential indications. Clinical Radiology, 2013, 68, 935-944.	1.1	96
89	Standalone computer-aided detection compared to radiologists' performance for the detection of mammographic masses. European Radiology, 2013, 23, 93-100.	4.5	16
90	Good correlation does not automatically imply good agreement: The trouble with comparing tumour size by breast MRI versus histopathology. European Journal of Radiology, 2013, 82, e906-e907.	2.6	15

#	Article	IF	CITATIONS
91	No increase of local recurrence rate in breast cancer patients treated with skin-sparing mastectomy followed by immediate breast reconstruction. Breast, 2013, 22, 1166-1170.	2.2	22
92	Axillary ultrasound for preoperative nodal staging in breast cancer patients: Is it of added value?. Breast, 2013, 22, 1108-1113.	2.2	66
93	Malignant lesions on mammography: accuracy of two different computer-aided detection systems. Clinical Imaging, 2013, 37, 283-288.	1.5	4
94	Noninvasive Nodal Staging in Patients With Breast Cancer Using Gadofosveset-Enhanced Magnetic Resonance Imaging. Investigative Radiology, 2013, 48, 134-139.	6.2	31
95	Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review. European Radiology, 2012, 22, 2607-2616.	4.5	64
96	Treatment response evaluation by MRI in breast cancer patients receiving neoadjuvant chemotherapy: there is more than just pathologic complete response prediction. Breast Cancer Research and Treatment, 2012, 136, 313-314.	2.5	8
97	Density is in the eye of the beholder: visual versus semi-automated assessment of breast density on standard mammograms. Insights Into Imaging, 2012, 3, 91-99.	3.4	25
98	Response monitoring of breast cancer patientsreceiving neoadjuvant chemotherapy using breast MRI – a review of current knowledge. Journal of Cancer Therapeutics & Research, 2012, 1, 34.	1.2	20
99	Gadofosveset-Enhanced Magnetic Resonance Imaging of Human Carotid Atherosclerotic Plaques. Investigative Radiology, 2010, 45, 275-281.	6.2	47
100	Molecular MRI of Early Thrombus Formation Using a Bimodal α2-Antiplasmin–Based Contrast Agent. JACC: Cardiovascular Imaging, 2009, 2, 987-996.	5.3	60
101	Atherosclerosis: Contrast-enhanced MR Imaging of Vessel Wall in Rabbit Model—Comparison of Gadofosveset and Gadopentetate Dimeglumine. Radiology, 2009, 250, 682-691.	7.3	39
102	Noninvasive diagnosis of ruptured peripheral atherosclerotic lesions and myocardial infarction by antibody profiling. Journal of Clinical Investigation, 2008, 118, 2979-85.	8.2	19
103	Is there more than C-reactive protein and fibrinogen?. Atherosclerosis, 2006, 187, 18-25.	0.8	73